Image: Courtesy of Michael Tolentino | ![]() |
![]() ![]() ![]() ![]() | |
![]() |
In the past few years, the media have written numerous, hopeful stories of how scientists are stifling tumors by inhibiting blood vessel growth. But the drugs based on this strategy--Endostatin, Neovastat, and thalidomide, for example--are still, in some cases, under unexpected scrutiny. As oncology researchers confront this reality, other investigators are looking at antiangiogenesis in a new way.
"Cancer is the disease that attracts everyone's attention, but there is angiogenesis research going on in other areas as well," says Peter J. Polverini, a neovascular specialist and dean of the University...
Interested in reading more?
![Magaizne Cover Magaizne Cover](https://cdn.the-scientist.com/assets/magazineIssueNo/1556/iImg/25891/april-2003-s.jpg)
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!